Testosterone
Judge questions difference between Hegseth’s testosterone policy and transgender care for troops
BLUF – The article reports that a federal judge questioned the Pentagon about the apparent inconsistency between its new policy encouraging testosterone replacement therapy for service members with medically diagnosed low testosterone and its continued prohibition on hormone therapy for transgender troops, asking the government to explain the differing medical and legal rationales as part of ongoing litigation over the transgender service ban. For Navy Medicine, the case highlights the complex intersection of military personnel policy, endocrine care, and medical ethics, underscoring the need for clinicians to apply evidence-based standards consistently while implementing Department of Defense policy and supporting affected service members.